Y. Chernajovsky

T. Stöver, A. Hoffmann, G. Gross, 2008, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Quantitative imaging of cartilage and bone for functional assessment of gene therapy approaches in experimental arthritis

R. Müller, C. Jorgensen, D. Noël, 2010, Journal of tissue engineering and regenerative medicine.

Gene Therapy for Chronic Relapsing Experimental Allergic Encephalomyelitis Using Cells Expressing a Novel Soluble p75 Dimeric TNF Receptor1

R. Neve, M. Feldmann, Y. Chernajovsky, 2000, The Journal of Immunology.

Gene Transfer to Lymphocytes Targeting Cartilaginous Collagen Type II

A. Annenkov, Y. Chernajovsky, 2002 .

Efficacy of Conditionally Replicative Adenoviruses

Y. Chernajovsky, David, L., 2019 .

Tumor Associated Stromal Cells Play a Critical Role on the Outcome of the Oncolytic Efficacy of Conditionally Replicative Adenoviruses

O. Podhajcer, Y. Chernajovsky, D. Gould, 2009, PloS one.

Production of Human Interferon in E. coli Under lac and tryplac Promoter Control

Y. Chernajovsky, S. Feinstein, Y. Mory, 1983, Annals of the New York Academy of Sciences.

Growth associated protein (GAP-43): Cloning and the development of a sensitive ELISA for neurological disorders

W. Heywood, K. Mills, G. Giovannoni, 2014, Journal of Neuroimmunology.

Latent cytokines for targeted therapy of inflammatory disorders

A. Annenkov, Y. Chernajovsky, D. Gould, 2014, Expert opinion on drug delivery.

Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma.

I. Fidler, S. Tucker, S. Pathak, 1991, Cancer research.

Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor

Y. Chernajovsky, D. Woodrow, R. Mageed, 1998, Gene Therapy.

A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors.

B. Hemmer, A. Annenkov, Y. Chernajovsky, 2011, Biochimica et biophysica acta.

Methods for targeting biologicals to specific disease sites.

Y. Chernajovsky, A. Nissim, S. Vessillier, 2004, Trends in molecular medicine.

Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.

M. Feldmann, R. Mullins, Y. Chernajovsky, 1995, The Journal of clinical investigation.

Prolonged Exposure of T Cells to TNF Down-Regulates TCRζ and Expression of the TCR/CD3 Complex at the Cell Surface1

A. Cope, A. Annenkov, B. Foxwell, 2001, The Journal of Immunology.

Development of Latent Cytokine Fusion Proteins

Y. Chernajovsky, D. Gould, Apostolos Koutsokeras, 2013 .

Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors.

M. Bar‐eli, Y. Chernajovsky, J. Killion, 1994, Cytokine.

Gene therapy for arthritis

P. Robbins, Y. Chernajovsky, C. Evans, 1998, Gene Therapy.

Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.

R. Kurzrock, H. Kantarjian, J. Gutterman, 1992, Cancer research.

Interferon-β Gene Therapy for the Treatment of Arthritis

Y. Chernajovsky, D. Gould, K. Triantaphyllopoulos, 2003 .

Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint.

D. Perrett, Y. Chernajovsky, G. Panayi, 2005, Arthritis and rheumatism.

Gene therapy for arthritis.

P. Robbins, Y. Chernajovsky, C. Evans, 2003, Gene therapy.

Dimeric TNF Receptor Using Cells Expressing a Novel Soluble p75 Experimental Allergic Encephalomyelitis Gene Therapy for Chronic Relapsing

R. Neve, M. Feldmann, Y. Chernajovsky, 2000 .

The Activity of Immunoregulatory T Cells Mediating Active Tolerance Is Potentiated in Nonobese Diabetic Mice by an IL-4-Based Retroviral Gene Therapy1

O. Podhajcer, M. Feldmann, L. Chatenoud, 2001, The Journal of Immunology.

Retroviral Gene Therapy Nonobese Diabetic Mice by an IL-4-Based Mediating Active Tolerance Is Potentiated in The Activity of Immunoregulatory T Cells

O. Podhajcer, M. Feldmann, L. Chatenoud, 2001 .

T cell receptor ζ reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor α

A. Cope, A. Annenkov, Y. Chernajovsky, 2004 .

Molecular engineering of short half-life small peptides (VIP, αMSH and γ3MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics

M. Perretti, Trinidad Montero-Melendez, Y. Chernajovsky, 2011, Annals of the rheumatic diseases.

and Lung Metastasis Established Colon and Mammary Tumors Induce the Immune-Mediated Eradication of IL-12 and IL-10 Expression Synergize to

O. Podhajcer, Y. Chernajovsky, V. López, 2005 .

Selective gamma-chain T-cell receptor gene rearrangements in a patient with Omenn's syndrome: absence of V-II subgroup (V gamma 9) transcripts

N. Day, Y. Chernajovsky, R. Good, 1996, Clinical and diagnostic laboratory immunology.

Synergism of glucocorticoids with granulocyte macrophage colony stimulating factor (GM-CSF) but not interferon gamma (IFN-gamma) or interleukin-4 (IL-4) on induction of HLA class II expression on human monocytes.

M. Feldmann, C. Hawrylowicz, Y. Chernajovsky, 1992, Cytokine.

Amelioration of collagen-induced arthritis and suppression of interferon-?, interleukin-12, and tumor necrosis factor ? production by interferon-? gene therapy

Richard O. Williams, Y. Chernajovsky, K. Triantaphyllopoulos, 1999 .

The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis.

Y. Chernajovsky, I. Chikanza, D. Kozaci, 2006, Rheumatology.

Generation of an efficiently secreted, cell penetrating NF‐κB inhibitor

Y. Chernajovsky, D. Gould, N. Purkayastha, 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta

A. Annenkov, Y. Chernajovsky, 2000, Gene Therapy.

Erythropoietin (EPO) Increases Myelin Gene Expression in CG4 Oligodendrocyte Cells through the Classical EPO Receptor

P. Ghezzi, A. Annenkov, Y. Chernajovsky, 2013, Molecular Medicine.

The murine p75 TNF receptor promoter region: DNA sequence and characterization of a cis-acting silencer.

M. Feldmann, M. Kissonerghis, Y. Chernajovsky, 1999, Molecular immunology.

Mutation of proline 211 reduces shedding of the human p75 TNF receptor.

Y. Chernajovsky, C. Herman, 1998, Journal of immunology.

Synthesis of human interferon beta 1 in Escherichia coli infected by a lambda phage recombinant containing a human genomic fragment.

J. Weissenbach, U. Nir, Y. Chernajovsky, 1981, European journal of biochemistry.

Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent

D. Scherman, P. Tak, C. Jorgensen, 2007, Annals of the rheumatic diseases.

Clustering of immunoreceptor tyrosine-based activation motif-containing signalling subunits in CD4(+) T cells is an optimal signal for IFN-gamma production, but not for the production of IL-4.

A. Annenkov, Y. Chernajovsky, T. Brocker, 2003, International immunology.

Gene therapy for arthritis – where do we stand?

Y. Chernajovsky, 2005, Arthritis research & therapy.

Commentary Gene therapy for arthritis - where do we stand?

Y. Chernajovsky, 2005 .

Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation.

G. Hitman, M. D. Turner, M. McDermott, 2005, Arthritis and rheumatism.

Different Therapeutic Outcomes in Experimental Allergic Encephalomyelitis Dependant Upon the Mode of Delivery of IL-10: A Comparison of the Effects of Protein, Adenoviral or Retroviral IL-10 Delivery into the Central Nervous System1

M. Feldmann, Y. Chernajovsky, D. Baker, 2001, The Journal of Immunology.

Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.

O. Podhajcer, Y. Chernajovsky, C. Carbone, 2000, Cancer research.

IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response

M. Ledda, Y. Chernajovsky, C. Carbone, 1999, Gene Therapy.

Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells

O. Podhajcer, Y. Chernajovsky, A. Bravo, 1999, Cancer Gene Therapy.

Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit.

Z. Eshhar, A. Annenkov, Y. Chernajovsky, 1998, Journal of immunology.

Regulation of expression and function of Lck tyrosine kinase by high cell density

Y. Chernajovsky, P. Kabouridis, P. Ozegbe, 2005, Molecular membrane biology.

Fighting cancer with oncolytic viruses

N. Lemoine, Y. Chernajovsky, L. Layward, 2006, BMJ : British Medical Journal.

Preferential Rearrangements of the VγI Subgroup of the γ‐Chain of the T‐Cell Antigen Receptor to Jγ2Cγ2 Gene Segments in Peripheral Blood Lymphocyte Transcripts from Normal Donors

Y. Chernajovsky, C. Platsoucas, G. Mathioudakis, 1993 .

Targeted delivery of anti-inflammatory therapy to rheumatoid tissue by fusion proteins containing an IL-4-linked synovial targeting peptide

C. Finucane, Y. Chernajovsky, S. Mather, 2011 .

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

J. Abbruzzese, P. Frost, R. Newman, 1993, British Journal of Cancer.

Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter.

Y. Chernajovsky, D. Novick, M. Rubinstein, 1984, DNA.

The molecular and cellular basis of corticosteroid resistance.

Y. Chernajovsky, I. Chikanza, D. Kozaci, 2003, The Journal of endocrinology.

TCR/CD3 Complex at the Cell Surface and Expression of the z Down-Regulates TCR Prolonged Exposure of T Cells to TNF

A. Annenkov, B. Foxwell, Y. Chernajovsky, 2001 .

Expression of human interferon genes using the recA promoter of Escherichia coli.

Y. Chernajovsky, L. Maroteaux, S. Feinstein, 1983, Nucleic acids research.

Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide

C. Finucane, Y. Chernajovsky, S. Mather, 2012, Annals of the rheumatic diseases.

The importance of understanding the molecular mechanisms of resistance to biologics.

Y. Chernajovsky, 2012, Rheumatology.

Inhibition of interleukin 2 production and alteration of interleukin 2 mRNA processing by human T-T cell hybridoma-derived suppressor factors.

F. Fox, Y. Chernajovsky, C. Platsoucas, 1994, Hybridoma.

Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3.

Y. Chernajovsky, S. Vessillier, G. Adams, 2005, Protein engineering, design & selection : PEDS.

Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies.

J. Weissenbach, M. Perricaudet, H. Soreq, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Inflammation‐inducible anti‐TNF gene expression mediated by intra‐articular injection of serotype 5 adeno‐associated virus reduces arthritis

D. Scherman, P. Tak, C. Jorgensen, 2007, The journal of gene medicine.

Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke

P. Vandenabeele, Z. Erbayraktar, P. Ghezzi, 2012, Proceedings of the National Academy of Sciences.

Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging.

D. García-Olmo, Y. Chernajovsky, M. Vilalta, 2008, Stem cells and development.

A novel doxycycline inducible autoregulatory plasmid which displays ‘on’/‘off’ regulation suited to gene therapy applications

Y. Chernajovsky, F. Ledda, H. Dreja, 2000, Gene Therapy.

Conversion of human interferon-β from a secreted to a phosphatidylinositol anchored protein by fusion of a 17 amino acid sequence to its carboxyl terminus

Y. Chernajovsky, G. Santillán, P. Orchansky, 1992, Molecular and Cellular Biochemistry.

STUDIES ON INTERFERON ACTION: SYNTHESIS, DEGRADATION AND BIOLOGICAL ACTIVITY OF (2′-5′) OLIGO-ISOADENYLATE

A. Kimchi, Y. Chernajovsky, M. Revel, 1979 .

Kinetics of the induction of three translation-regulatory enzymes by interferon.

A. Kimchi, Y. Chernajovsky, M. Revel, 1979, Proceedings of the National Academy of Sciences of the United States of America.

ROLE OF INTERFERON‐INDUCED ENZYMES IN THE ANTIVIRAL AND ANTIMITOGENIC EFFECTS OF INTERFERON

A. Kimchi, Y. Chernajovsky, E. Yakobson, 1980, Annals of the New York Academy of Sciences.

Differential effects of two interferon-induced translational inhibitors on initiation of protein synthesis.

A. Zilberstein, A. Kimchi, Y. Chernajovsky, 1979, European journal of biochemistry.

Recent developments in retroviral-mediated gene transduction.

Y. Chernajovsky, G. Daly, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis

Y. Chernajovsky, D. Baker, J. Croxford, 1998, Gene Therapy.

Constitutive in vitro binding of nuclear proteins to the 5'‐fanking region of 6–16, a human gene inducible by α, β‐interferons

Y. Chernajovsky, 1989 .

Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats.

M. Feldmann, A. Corcoran, Y. Chernajovsky, 1994, European journal of biochemistry.

Interferon response element of the human gene 6‐16.

G. Stark, I. Kerr, T. Dale, 1988, The EMBO journal.

Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis.

A. Annenkov, Y. Chernajovsky, H. Dreja, 2000, Arthritis and rheumatism.

Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.

M. Feldmann, Y. Chernajovsky, D. Baker, 1998, Journal of immunology.

Engineering stem cells for therapy.

A. Annenkov, Y. Chernajovsky, Chris Hughes, 2006, Regenerative medicine.

Anti-Collagen Antibody and Fc Receptor Containing Single-Chain Fv of an Chimeric Cell Hybridomas Transduced with a Loss of Original Antigenic Specificity in T

Z. Eshhar, A. Annenkov, Y. Chernajovsky, 2017 .

Highly efficient gene transfer into antigen‐specific primary mouse lymphocytes with replication‐deficient retrovirus expressing the 10A1 envelope protein

A. Annenkov, Y. Chernajovsky, G. Daly, 2002, The journal of gene medicine.

Loss of Original Antigenic Specificity in T Cell Hybridomas Transduced with a Chimeric Receptor Containing Single-Chain Fv of an Anti-Collagen Antibody and FcεRI-Signaling γ Subunit

Z. Eshhar, A. Annenkov, Y. Chernajovsky, 1998, The Journal of Immunology.

The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal‐cell carcinoma grown in nude mice

I. Fidler, S. Pathak, P. Frost, 1992, International journal of cancer.

Gene Therapy for Rheumatoid Arthritis

O. Podhajcer, D. Baker, A. Annenkov, 1998, Drugs & aging.

Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application

Y. Chernajovsky, H. Mohamed, D. Gould, 2016, Scientific Reports.

Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth

O. Podhajcer, Y. Chernajovsky, D. Gould, 2006, Molecular Cancer Therapeutics.

Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells

O. Podhajcer, Y. Chernajovsky, L. Bover, 1997, Nature Medicine.

Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor.

P. Robbins, M. Feldmann, Y. Chernajovsky, 1995, Gene therapy.

IL-12 and IL-10 Expression Synergize to Induce the Immune-Mediated Eradication of Established Colon and Mammary Tumors and Lung Metastasis1

O. Podhajcer, Y. Chernajovsky, A. Bravo, 2005, The Journal of Immunology.

Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy.

Y. Chernajovsky, K. Triantaphyllopoulos, R. Williams, 1999, Arthritis and rheumatism.

Immuno- and genetic therapy in autoimmune diseases

A. Annenkov, Y. Chernajovsky, R. Mageed, 2000, Genes and Immunity.

Monoclonal Antibodies for Purification and RIA of Natural and Recombinant Human Interferon-α, -β And-γ

Z. Eshhar, Y. Chernajovsky, D. Novick, 1985 .

Advances in Understanding the Genetic Basis of Rheumatoid Arthritis and Osteoarthritis

Y. Chernajovsky, P. Winyard, P. Kabouridis, 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

The role of receptor-ligand endocytosis and degradation in interleukin-2 signaling and T-lymphocyte proliferation.

Y. Chernajovsky, S. Legrue, T. Sheu, 1991, Lymphokine and cytokine research.

Pathogenic lymphoid cells engineered to express TGF β1 ameliorate disease in a collagen-induced arthritis model

Y. Chernajovsky, K. Triantaphyllopoulos, G. Adams, 1997, Gene Therapy.

Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor–associated periodic syndrome interacts with wild‐type tumor necrosis factor receptor I and induces ligand‐independent NF‐κB activation

G. Hitman, M. D. Turner, M. McDermott, 2005 .

Differences between disease‐associated endoplasmic reticulum aminopeptidase 1 (ERAP1) isoforms in cellular expression, interactions with tumour necrosis factor receptor 1 (TNF‐R1) and regulation by cytokines

P. Munroe, A. Onipinla, M. Caulfield, 2015, Clinical and experimental immunology.

A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation.

J. Hirabayashi, M. Perretti, Y. Chernajovsky, 2003, The American journal of pathology.

Recombinant Galectin-1 and Its Genetic Delivery Suppress Collagen-Induced Arthritis via T Cell Apoptosis

G. Rabinovich, J. Hirabayashi, Y. Chernajovsky, 1999, The Journal of experimental medicine.

Inhibition of established collagen-induced arthritis with a tumour necrosis factor-α inhibitor expressed from a self-contained doxycycline regulated plasmid

Y. Chernajovsky, D. Gould, Carly Bright, 2003, Arthritis research & therapy.

Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.

Y. Chernajovsky, L. Bover, C. Carbone, 1996, Cellular and molecular biology.

Targeting cytokines to inflammation sites

Yuti Chernajovsky, Y. Chernajovsky, Gill Adams, 2003, Nature Biotechnology.

Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

O. Podhajcer, D. Curiel, Y. Chernajovsky, 2013, The Journal of investigative dermatology.

Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor‐β1

V. Prassolov, Y. Chernajovsky, M. Sudomoina, 2004 .

Human p75 TNF Receptor Mutation of Proline 211 Reduces Shedding of the

Y. Chernajovsky, Charlotte Herman, 2022 .

Gene therapy for autoimmune diseases: quo vadis?

O. Podhajcer, Y. Chernajovsky, D. Gould, 2004, Nature Reviews Immunology.

Gene therapy with an improved doxycycline-regulated plasmid encoding a tumour necrosis factor-alpha inhibitor in experimental arthritis

Y. Chernajovsky, D. Gould, N. Yousaf, 2007, Arthritis research & therapy.

Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes

Y. Chernajovsky, A. Claxson, P. Winyard, 2003, Gene Therapy.

Perspectives for the future developments of gene therapy for autoimmune and inflammatory therapy

P. Robbins, Y. Chernajovsky, 2010 .

A novel hybrid promoter responsive to pathophysiological and pharmacological regulation

O. Podhajcer, Y. Chernajovsky, D. Gould, 2011, Journal of Molecular Medicine.

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.

G. Hitman, P. Hawkins, M. D. Turner, 2008, Arthritis and rheumatism.

Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β

Hansjörg Hauser, David Baker, Yuti Chernajovsky, 2014, Expert opinion on drug delivery.

A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints

H. Hauser, M. Köster, Y. Chernajovsky, 2013, Annals of the rheumatic diseases.

Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of L-cystine.

Y. Chernajovsky, L. Mullen, G. Adams, 2012, Journal of biotechnology.

Gene therapy targets for rheumatoid arthritis

Y. Chernajovsky, I. Chikanza, D. Gould, 2000 .

Immune-mediated inflammation across disease boundaries: breaking down research silos

P. Tak, Y. Chernajovsky, E. Waterman, 2021, Nature Immunology.

Endogenous GATA factors bind the core sequence of the tetO and influence gene regulation with the tetracycline system.

Y. Chernajovsky, D. Gould, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.

R. Vile, Y. Chernajovsky, I. Hart, 1994, Gene therapy.

Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives.

M. Feldmann, Y. Chernajovsky, R. Maini, 1995, British medical bulletin.

Comment on: Low TNF-induced NF-κB and p38 phosphorylation levels in leucocytes in tumour necrosis factor receptor-associated periodic syndrome.

M. D. Turner, Y. Chernajovsky, 2011, Rheumatology.

Transformation injury and the unicellular phenotype of malignant cells

P. Frost, Y. Chernajovsky, 1990, Cancer and Metastasis Reviews.

Characterization of a human gene inducible by alpha‐ and beta‐interferons and its expression in mouse cells.

G R Stark, G. Stark, I. Kerr, 1986, The EMBO journal.

Transfection of thyroid autoantigens into EBV-transformed B cell lines. Recognition by Graves' disease thyroid T cells.

M. Feldmann, R. Mullins, Y. Chernajovsky, 1994, Journal of immunology.

Prolonged stimulation by TNF uncouples T cell receptor (TCR) signalling pathways at many levels

A. Annenkov, Y. Chernajovsky, A. Cope, 2002, Arthritis Research.

Interleukin‐4 inhibits χ light chain expression and NFχB activation but not IχBα degradation in 70Z/3 murine pre‐B cells

K. Sugamura, M. Feldmann, B. Foxwell, 1995, European journal of immunology.

Effects of APC De-Targeting and GAr Modification on the Duration of Luciferase Expression from Plasmid DNA Delivered to Skeletal Muscle

Y. Chernajovsky, J. Rice, D. Gould, 2014, Current gene therapy.

Systemic gene therapy for arthritis.

Y. Chernajovsky, 1999, Drugs of today.

Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist.

R. Neve, M. Feldmann, M. Kissonerghis, 1996, Cytokine.

AMELIORATION OF COLLAGEN-INDUCED ARTHRITIS AND SUPPRESSION OF INTERFERON- (cid:103) , INTERLEUKIN-12, AND TUMOR NECROSIS FACTOR (cid:97) PRODUCTION BY INTERFERON- (cid:98) GENE THERAPY

Richard O. Williams, Y. Chernajovsky, K. Triantaphyllopoulos, 1999 .

T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha.

A. Cope, A. Annenkov, Y. Chernajovsky, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Development of new molecules, vectors and cells for therapy of arthritis.

A. Annenkov, Y. Chernajovsky, D. Gould, 2003, Joint, bone, spine : revue du rhumatisme.

Gene transfer as therapy for rheumatoid arthritis: why, what and how?

Y. Chernajovsky, 1999, Rheumatology.

Targeting therapeutics to arthritic joints by antibody specific to post-translationally modified collagen type II

F. Dell’Accio, Y. Chernajovsky, A. Manzo, 2012 .

Family of human alpha-interferon-like sequences

U. Nir, Y. Chernajovsky, L. Maroteaux, 1985, Molecular and cellular biology.

Kinetics of the induction of three translation-regulatory enzymes by interferon.

A. Kimchi, Y. Chernajovsky, M. Revel, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.

G. Hitman, P. Hawkins, M. D. Turner, 2008, Arthritis and rheumatism.

Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.

B. Scallon, J. Ghrayeb, M. Feldmann, 1998, European cytokine network.